GlassScriptPhysician profile
Ladynez Espinal
NPI 1023121563
$800.50
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $275 · 2020: $181 · 2021: $188 · 2022: $134 · 2024: $22.32.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $22.32.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $22.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $254.49 | 2019-2022 | |
| Allergan, INC. | $128.90 | 2019 | |
| Lupin INC. | $120.55 | 2019-2021 | |
| Coopersurgical, INC. | $108.44 | 2020-2022 | |
| Evofem Biosciences, INC. | $62.05 | 2021-2024 | |
| Amag Pharmaceuticals, INC. | $33.22 | 2019 | |
| Therapeuticsmd, INC. | $30.44 | 2020-2021 | |
| Abbott Laboratories | $24.91 | 2022 | |
| Hologic Sales and Service, LLC | $21.24 | 2019 | |
| Millicent US INC | $16.26 | 2021 |
7 companies reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ladynez Espinal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.